PROQR THRAPEUTICS N V's ticker is PRQR and the CUSIP is N71542109. A total of 55 filers reported holding PROQR THRAPEUTICS N V in Q1 2023. The put-call ratio across all filers is 0.84 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $46,178 | -83.2% | 21,680 | -92.9% | 0.00% | -100.0% |
| Q1 2022 | $275,000 | -90.0% | 303,356 | -11.3% | 0.00% | -85.7% |
| Q4 2021 | $2,740,000 | -38.2% | 342,083 | -35.4% | 0.01% | -53.3% |
| Q3 2021 | $4,435,000 | +12.3% | 529,883 | -9.5% | 0.03% | +20.0% |
| Q2 2021 | $3,948,000 | – | 585,806 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aquilo Capital Management, LLC | 748,861 | $6,815,000 | 2.37% |
| Opus Point Partners Management, LLC | 138,461 | $1,260,000 | 1.86% |
| RTW INVESTMENTS, LP | 3,722,950 | $33,879,000 | 1.81% |
| Kerrisdale Advisers, LLC | 465,580 | $4,237,000 | 1.52% |
| DAFNA Capital Management LLC | 261,521 | $2,380,000 | 0.90% |
| SPHERA FUNDS MANAGEMENT LTD. | 470,000 | $4,277,000 | 0.58% |
| Artal Group S.A. | 1,300,000 | $11,830,000 | 0.48% |
| Orbimed Advisors | 1,382,502 | $12,581,000 | 0.20% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 56,000 | $511,000 | 0.19% |
| ALTRINSIC GLOBAL ADVISORS LLC | 201,360 | $1,832,000 | 0.08% |